All In MedTech

FDA Clearance Tracker · P100047-S139

HeartWare HVAD System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 21, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 21, 2019

Approved

Time to decision

179 days

Received Apr 25, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P100047-S139
Device name
HeartWare HVAD System
Applicant
Medtronic
Applicant location
Mounds View, MN
Received
Apr 25, 2019
Decided
Oct 21, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100047

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

Approval for revisions to the Instructions for Use to include findings from the Bridge-to-Transplant PAS03 study and data from longer term follow-up of ENDURANCE Supplemental study subjects.

Source documents

Other decisions for Medtronic

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.